Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05180994Phase 1Recruiting

Topical Infliximab in Eyes With Penetrating Keratoplasty

Role: collaborator

NCT04750447Unknown

Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C

Role: lead

NCT05126069Completed

Ab Interno Gelatin Microstent With MMC vs. Trabeculectomy With MMC: 3 Year Retrospective Cohort Analysis

Role: lead

NCT04454138Completed

Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement

Role: lead

All 4 trials loaded